Meeting
2019 ASCO Annual Meeting
EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.
Authors
Christopher J. Hoimes
University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH
Christopher J. Hoimes , Jonathan E. Rosenberg , Daniel Peter Petrylak , Anne-Sophie Carret , Amal Melhem-Bertrandt , Thomas W. Flaig
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT03288545
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS4593)
DOI
10.1200/JCO.2019.37.15_suppl.TPS4593
Abstract #
TPS4593
Poster Bd #
415b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.
First Author: Nataliya Mar
Poster
2019 Genitourinary Cancers Symposium
EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).
First Author: Daniel Peter Petrylak
Poster
2023 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.
First Author: Peter H. O'Donnell
Poster
2020 ASCO Virtual Scientific Program
Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
First Author: Jonathan E. Rosenberg